Cryptococcosis Therapeutics Market Size, Share, Opportunities, And Trends By Treatment (Amphotericin B, Flucytosine, Fluconazole Drugs, Voriconazole), By Diagnostic (Cryptococcal Antigen, Chest X-ray, Lumbar Puncture, Urine Test), By End-User (Hospitals, Ambulatory Surgical Centers, Others), And By Geography - Forecasts From 2023 To 2028

  • Published : Aug 2023
  • Report Code : KSI061616010
  • Pages : 141

The cryptococcosis therapeutics market is expected to grow at a CAGR of 8.69% from US$27.723 billion in 2021 to US$49.678 billion in 2028.

Cryptococcus neoformans and Cryptococcus gattii are the fungi that produce the fungal illness known as cryptococcosis, which mostly affects the lungs and central nervous system. People who have weaker immune systems due to illnesses like AIDS, Hodgkin lymphoma, sarcoidosis, or solid organ transplantation are typically more vulnerable to this form of infection. Inhaling dust that contains yeast cells can cause cryptococcosis, which commonly affects the lungs. The clinical and microscopic diagnosis of cryptococcosis is supported by culture or fixed-tissue staining.

Opportunities for the cryptococcosis market to increase

Cryptococcocis neoformans and Cryptococcocis gattii cause the chronic fungal disease known as cryptococcosis in humans, sometimes known as European blastomycosis or tollosis. Fungi, which are also present in dirt and dust, are regularly detected in pigeon droppings. Numerous fungi can also be found in window frames and other common nesting locations. Cryptococcosis is an issue on a global scale. Human immunodeficiency virus (HIV) infection is the leading cause of death for individuals who have it, especially in sub-Saharan Africa.

People suffering from cryptococcosis disease are increasing

In 2022, the World Health Organisation and the Centres for Disease Control and Prevention predicted that there will be around 220,000 cases of cryptococcal meningitis among individuals with HIV/AIDS each year, resulting in an estimated 181,000 fatalities. Antifungal medications, immunomodulatory treatments, and supportive care are already available as treatment options. Cryptococcosis continues to be a major cause of AIDS-related deaths globally, even though antiretroviral treatment (ART) has shown some promise in lowering cases which is a major growth driver for the cryptococcosis therapeutics market. It is crucial to develop more efficient therapies to lessen the burden of this fungus infection, enhance patient outcomes, and address this enduring worldwide concern.

The growing use of Amphotericin B

Amphotericin B is helpful as the initial therapy for infections caused by extensive cryptococcosis. According to the research article that was published in the New England Journal of Medicine in March 2022, the World Health Organization's recommended treatment included amphotericin B deoxycholate flucytosine for 7 days. Amphotericin B binds to ergosterol in the fungal cell membrane, causing holes to develop, ions to flow out, and eventually the death of the fungal cells. These advantages of amphotericin B in the treatment of cryptococcal meningitis fuel the cryptococcosis therapeutics market growth.

Increasing organ transfer drive

Immunosuppressant medications are needed after organ transplant therapy to stop the immune system from attacking or rejecting the donor organ. The cryptococcosis therapeutics market demand for immunosuppressant medications is developing as a result of the rising number of organ transplants. The patients' immunity is weakened by the increasing number of organ transplants and the usage of immunosuppressants. The risk of infection from cryptococcosis is greater in persons who have had organ transplants due to inadequate immunity, which will propel the expansion of the cryptococcosis therapeutics industry throughout the projected period.

Cryptococcal Antigen Test is anticipated to dominate the market

The market share of the Cryptococcal Antigen Test is expected to rise considerably throughout the forecast period. A common method for diagnosing cryptococcosis is the Cryptococcus fungus identification in clinical specimens, frequently from cerebrospinal fluid (CSF) or respiratory samples, using the Cryptococcal Antigen Test. The detection of Cryptococcal antigen in serum or CSF is a very sensitive and precise diagnostic test for cryptococcosis. Since it can quickly and accurately establish the fungus's existence, it is commonly used in clinical settings for diagnosis and determining the effectiveness of treatments. For instance, Thermofisher introduced the Remel Cryptococcus Antigen Test Kit, which is simple to use and has diagnostic and prognostic value.

The North American cryptococcosis market is projected to propel  

There are several reasons why North America dominates the cryptococcosis therapeutics industry. First off, compared to other locations, the region has a greater prevalence of HIV/AIDS, creating a larger patient base in need of efficient cryptococcosis therapies. Leading pharmaceutical firms and research facilities that have made a substantial contribution to the creation of cryptococcosis medicines are also located in North America. The National Multiple Sclerosis Society estimates that there will be close to one million MS patients in the US by 2022. The rising frequency of numerous autoimmune illnesses in the US also contributes to the global cryptococcosis therapeutics market growth.

Middle East and Africa show a high prevalence of HIV/AIDS

Approximately 20.6 million (18.9 million-23.0 million) people, or 54% of all HIV-positive people worldwide, live in Eastern and Southern Africa, according to the Joint United Nations Programme on HIV/AIDS (UNAIDS) report 2022. At the end of 2021, 5 million (4.5 million–5.6 million) people in Western and Central Africa were HIV-positive. The danger of cryptococcosis in this area is increased by the prevalence of HIV and AIDS, which drives the expansion of the global cryptococcosis therapeutics market.

Market Key Developments

  • In December 2022, Cresemba Capsule 100 mg and Cresemba Intravenous Infusion 200 mg (isavuconazonium sulfate) acquired authorization for production and distribution in Japan by Asahi Kasei Pharma for the aim of treating fungal illnesses including aspergillosis, mucormycosis, and cryptococcosis.
  • In June 2022, the authorized generic versions of a few over-the-counter medications were purchased by Glenmark Pharmaceuticals Ltd. from Wockhardt Ltd. in the US. The company's wholly-owned subsidiary in the United States, Glenmark Pharmaceuticals Inc., has acquired the authorized abbreviated new drug applications (ANDAs) for the 10 mg and 20 mg famotidine tablets used to treat and prevent stomach and intestinal ulcers.


  • By Treatment
    • Amphotericin B
    • Flucytosine
    • Fluconazole Drugs
    • Voriconazole
  • By Diagnostic
    • Cryptococcal Antigen
    • Chest X-ray
    • Lumbar Puncture
    • Urine Test
  • By End-User
    • Hospitals
    • Ambulatory Surgical Centers
    • Others
  • By Geography
    • North America
      • United States
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • United Kingdom
      • Germany
      • France
      • Spain
      • Others
    • Middle East and Africa
      • Saudi Arabia
      • UAE
      • Israel
      • Others
    • Asia Pacific
      • Japan
      • China
      • India
      • South Korea
      • Indonesia
      • Thailand
      • Others

Frequently Asked Questions (FAQs)

The cryptococcosis therapeutics market is expected to reach a market size of US$49.678 billion by 2028.
Cryptococcosis Therapeutics Market was valued at US$27.723 billion in 2021.
The global cryptococcosis therapeutics market is expected to grow at a CAGR of 8.69% over the forecast period.
North America is expected to hold a significant share of the cryptococcosis therapeutics market.
A significant factor anticipated to drive the growth of the cryptococcosis therapeutics market is the increasing prevalence of immunocompromised conditions.


1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline


2.1. Research Data

2.2. Assumptions


3.1. Research Highlights


4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis


5.1. Introduction

5.2. Amphotericin B

5.3. Flucytosine

5.4. Fluconazole Drugs

5.5. Voriconazole


6.1. Introduction

6.2. Cryptococcal Antigen

6.3. Chest X-ray

6.4. Lumbar Puncture

6.5. Urine Test


7.1. Introduction

7.2. Hospitals

7.3. Ambulatory Surgical Centers

7.4. Others


8.1. Introduction

8.2. North America

8.2.1. United States

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. United Kingdom

8.4.2. Germany

8.4.3. France

8.4.4. Spain

8.4.5. Others

8.5. The Middle East and Africa

8.5.1. Saudi Arabia

8.5.2. UAE

8.5.3. Israel

8.5.4. Others

8.6. Asia Pacific

8.6.1. Japan

8.6.2. China

8.6.3. India

8.6.4. South Korea

8.6.5. Indonesia

8.6.6. Thailand

8.6.7. Others


9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Vendor Competitiveness Matrix


10.1. Gilead Sciences

10.2. Cureus

10.3. VIC Health

10.4. Astellas Pharma Inc.

10.5. Novartis AG

10.6. Pfizer Inc.

10.7. Glenmark Pharmaceuticals

10.8. Lupin Ltd.

Gilead Sciences


VIC Health

Astellas Pharma Inc.

Novartis AG

Pfizer Inc.

Glenmark Pharmaceuticals

Lupin Ltd.